Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

EcoCeres Inc., a producer of sustainable fuel backed by Bain Capital, is exploring an initial public offering that could ...

Chinese soda maker Dayao is gearing up for a Hong Kong initial public offering as early as the second half of 2025, people ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

IPO began trading Friday on the NASDAQ. Shares opened at $17.25 per ADS, in line with the initial public offering (IPO) price of $17.25. The pharmaceutical company, already listed on the Main Board of ...

Phoenix Asia Holdings faces significant risks, including regulatory risks, customer concentration and uncertainties in the ...

CTRL Group (MCTR) priced 2M shares at $4.00, at the low end of the $4.00-$5.00 range. Revere is acting as sole book running manager for the ...

The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

Chinese HR service provider 51job is set to go public in Hong Kong after its privatization in 2022, according to Chinese ...

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

CHINESE soda maker Dayao is gearing up for a Hong Kong initial public offering (IPO) as early as the second half of 2025, ...

The Inner Mongolia-based maker of carbonated beverages, juices and protein drinks is working with advisers on the size and ...